Scarica l'app Stockscreener
57.06
3.91%
-2.32
Dopo l'orario di chiusura:
57.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$59.38
Aprire:
$59.77
Volume 24 ore:
2.53M
Relative Volume:
2.68
Capitalizzazione di mercato:
$1.95B
Reddito:
$55.63M
Utile/perdita netta:
$-158.10M
Rapporto P/E:
-6.7766
EPS:
-8.4202
Flusso di cassa netto:
$-203.94M
1 W Prestazione:
-14.96%
1M Prestazione:
-23.88%
6M Prestazione:
-20.84%
1 anno Prestazione:
+2.59%
Intervallo 1D:
$57.04
$60.98
Intervallo di 1 settimana:
$56.21
$69.84
Portata 52W:
$33.40
$109.00
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
57.06 | 1.95B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Wedbush | Neutral |
| 2026-03-17 | Iniziato | TD Cowen | Buy |
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics Director Roy Whitfield Reports Acquisition of RSUs and Stock Options - Kalkine Media
Form 4 Nektar Therapeutics For: 25 September By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. - Stock Titan
A director receives 2,000 stock units alongside 4,000 options at Nektar Therapeutics (NKTR). - Stock Titan
Director Robert Chess also received 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Director Diana Brainard receives 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly By Investing.com - Investing.com South Africa
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - prnewswire.com
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters
Microsoft, Nike, Nektar Therapeutics - TradingView
Nektar Therapeutics Wins $90M Lilly Verdict - grafa.com
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly - Investing.com
Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord
Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - Dealroom
Nektar prevails in legal battle with Lilly over broken rezpeg partnership - BioSpace
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal - Yahoo Finance
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - Benzinga
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target - TradingView
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update - Morningstar
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data - Yahoo Finance
Why is Nektar Therapeutics stock climbing today? - Investing.com
Form 8K Nektar Therapeutics For: 25 September By Investing.com - Investing.com India
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada
Nektar gains 5% as jury awards $90M plus interest in Lilly trial - TradingView
Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute - TradingView
Nektar TherapeuticsJury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement - TradingView
Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - law360.com
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics stock gains 2.98 percent on trial watch - AD HOC NEWS
Wedbush maintains Neutral rating on Nektar Therapeutics, $50 price target - TradingView
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics stock falls 9.6 percent as patent case weighs - AD HOC NEWS
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Nektar Therapeutics drops as jury deliberates in Eli Lilly dispute over Rezpeg - TradingView
How Investors Are Reacting To Nektar Therapeutics (NKTR) Index Reclassification - simplywall.st
Nektar Therapeutics(NasdaqCM: NKTR) added to S&P Biotechnology Select Industry Index - marketscreener.com
Nektar Therapeutics(NasdaqCM:NKTR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Nektar Therapeutics (NKTR), What Is Drawing Fresh Attention Now? - simplywall.st
Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End - law360.com
Nektar Therapeutics stock gains after Q2 loss narrows - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire
Nektar Therapeutics options flow shows bullish bets against a bearish tape - Investing.com
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told - Law360
Nektar CEO Opens Door To Finance Questions In Eli Lilly Trial - Law360
Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata - The Clinical Trial Vanguard
Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360
Lancet Phase 2b REZOLVE-AD Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In? - simplywall.st
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect | NDAQ:NKTR | Press Release - stockhouse.com
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):